Clinical trial
Toripalimab in Combination With Cetuximab，Cisplatin and 5-FU for Conversion Therapy of Locally Nonresectable Oral Cavity Squamous Cell Carcinoma （OCSCC）
NCT06081582 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Toripalimab in Combination With Cetuximab，Cisplatin and 5-FU for Conversion Therapy of Locally Nonresectable Oral Cavity Squamous Cell Carcinoma （OCSCC）
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 6, 2023
- Completion date
- November 30, 2024
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.